Clinical Trial Search

Primary: Objective Response Rate (ORR) — 48.7; 27.3 Percentage of participants

Primary: Percentage of Time With Sensor Glucose Values Between 70 and 180 Milligrams Per Deciliter (mg/dL) (24-Hour) — 76.98; 77.84 Percentage of Time — p=0.339

Primary: Area Under the Plasma Fibrinogen Concentration-time Curve (AUC) From Time Zero to 14 Days (AUC0-14days) of FIB Grifols Determined by Clauss Method, Dose Normalized to 70…

Primary: Least Square (LS) Mean Change From Baseline Forced Expiratory Volume in 1 Second (FEV1) to Peak FEV1 at Week 4 — 0.1963; 0.2100; 0.2260; 0.2431 liters — p=0.0008

Primary: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL — 33; 43 Participants

Primary: BICR-Assessed Objective Response Rate (ORR) — 6.4; 26.3 Percentage of participants

Primary: PFS, Assessed Using Standard RECIST Criteria — 58 percentage of participants

Primary: Rate of Clinical Benefit — 0; 0; 6; 11 Participants

Primary: Standing Vertigo Intensity — 165.10; 155.10; 136.60 mm*day — p=0.8466

Primary: Change From Baseline to Week 12/End of Treatment (EoT) in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery…

Primary: Clinical Response — 54; 48; 47; 6 Participants

Primary: Compensatory Signaling/Feedback Loop Signaling Evaluated by Measurement of Phosphorylated (p)-EGFR

Primary: Biomarkers in Blood and Archived Tissue Samples, and Their Correlation With Clinical Activity in Subjects With Advanced Renal Cell Cancer Treated With Tivozanib.

Primary: Change in Tumor Infiltration by Cluster of Differentiation 8 (CD8) Positive Cytotoxic T Lymphocytes — 289; 104; 955; 428 cells/mL

Primary: Methamphetamine Self-Administration — 8890; 7116 Clicks on a computer mouse